Back to News
Market Impact: 0.42
Novo scraps two more heart drug trials, further dimming growth beyond obesity
Source: reuters.com
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Novo Nordisk halted two additional clinical trials of experimental cardiovascular drug ziltivekimab, further weakening its effort to diversify beyond its blockbuster obesity and diabetes franchises. The discontinuations raise pipeline-development risk and increase the company's reliance on its core GLP-1 portfolio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
NVO-0.82
More News
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- PG&E’s CEO says AI is ‘the best thing that could’ve ever happened to the grid’
- Defense giant Saab sees orders triple after Gripen fighter jet deal with Ukraine
- Volvo Cars shares plunge 25% amid China sales slump and fresh job cuts
- Mark Zuckerberg owns 13% of Meta but controls 61% of its votes. California’s wealth tax would bill him on the 13%
- Eni Raises Investor Payouts as High Fuel Prices Boost Cash Flow